Japan College of Rheumatology to Collaborate with Pfizer on PMS, Warns that Non-RA Specialists More Inclined to Prescribe Xeljanz

The Japan College of Rheumatology President Yoshinari Takasaki The Japan College of Rheumatology will cooperate with Pfizer Japan on post-marketing surveillance (PMS) of the company’s new oral rheumatoid arthritis (RA) treatment Xeljanz (tofacitinib) to collect data including that on efficacy,...read more